In addition, anti-PD-L1 antibody inhibited TRAIL-mediated metastasis in mice. Thus, TRAIL has the potential to act as a key molecule to target EMT and inhibit ESCC progression in the future. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.